<unk> , sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells.<unk>  specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.<unk>  is given as a continuous IV infusion for 28 consecutive days per cycle. The dose depends on a patient's actual body weight. Patients weighing over 45 kg should receive fixed doses while patients weighing less than 45 kg should receive doses based on their estimated body surface area.
Blinatumomab
Loncastuximab tesirine
Margetuximab
Tositumomab
Siltuximab
Dinutuximab
Isatuximab
Polatuzumab vedotin